David A. Lowe

Chief Operating Officer
PsychoGenics Inc., Tarrytown, NY
E-mail: david.lowe@psychogenics.com
Page: http://www.psychogenics.com/seniormanagement.html

Fields of interest

Neuropharmacology, drug development.

 

Recent publications

Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, Xie W, Rowe WB, Ong V, Graham E, Terry AV Jr, Rodefer JS, Herbert B, Murray M, Porter R, Santarelli L, Lowe DA.:
RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.
J Pharmacol Exp Ther., 2011, 336(1):242-53

Liu J, Yu LF, Eaton JB, Caldarone B, Cavino K, Ruiz C, Terry M, Fedolak A, Wang D, Ghavami A, Lowe DA, Brunner D, Lukas RJ, Kozikowski AP.:
Discovery of isoxazole analogues of sazetidine-A as selective α4β2-nicotinic acetylcholine receptor partial agonists for the treatment of depression.
J Med Chem., 2011, 54(20):7280-8

Paterson NE, Min W, Hackett A, Lowe D, Hanania T, Caldarone B, Ghavami A.:
The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
Prog Neuropsychopharmacol Biol Psychiatry., 2010, 34(8):1455-64

Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM.:
Therapeutics for cognitive aging
Ann N Y Acad Sci., 2010, 1191 Suppl 1:E1-15.

Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, Spaulding V, Bennett F, Lowe L, Andreyeva T, Lowe D, Lane S, Thom G, Valge-Archer V, Gill D, Young D, Bloom L.:
In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.
MAbs., 2010, 2(3):335-46

Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, Lowe DA.:
Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.
Psychopharmacology (Berl)., 2003, 165(2):128-35